SOURCES SOUGHT
A -- Beryllium Exposures in Human HLA-DP Transgenic Mouse Model
- Notice Date
- 2/22/2007
- Notice Type
- Sources Sought
- NAICS
- 541710
— Research and Development in the Physical, Engineering, and Life Sciences
- Contracting Office
- Department of Health and Human Services, Center for Disease Control and Prevention, Acquisition and Assistance Field Branch (Morgantown), 1095 Willowdale Road, Morgantown, WV, 26505, UNITED STATES
- ZIP Code
- 00000
- Solicitation Number
- Reference-Number-000HCCHB-2007-40608
- Response Due
- 3/9/2007
- Archive Date
- 4/9/2007
- Description
- NOTICE OF INTENT TO ISSUE A PURCHASE ORDER. The Centers for Disease Control and Prevention (CDC), the National Institute for Occupational Safety and Health, ALOSH, Morgantown, WV, and Pathology and Physiology Research Branch (PPRB) in collaboration with the Division of Respiratory Disease Studies (DRDS) is conducting a study to elucidate the molecular mechanism that constitutes the basis for chronic beryllium disease (CBD). Together they were awarded funding to conduct studies specifically designed to compare the adverse effects of different types of beryllium and to gather dose response data. Until recently, no animal model for CBD existed. HELD scientists identified three members of the HLA-DPB1 gene family that were suitable to genetically engineer mouse model of CBD, a transgenic mouse called the CBD mouse model. Department of Energy (DOE) supported scientists at Lawrence Berkley National Laboratories and New York University developed and refined the CBD mouse model. The model consists of three mouse strains (one for each of the HLA-DPB1 family members, designated: *0201, *0401 and *1701). The study being conducted by HELD and DRDS has multiple objectives, these are: 1) to provide a validated transgenic mouse model of CBD for the research community, to be disseminated through JAX Labs. Inc.; 2) to provide data concerning the differential toxicity of beryllium materials in the mouse model that can be used for informed control technology decisions; 3) to provide data to support or refute skin as a route of exposure for beryllium sensitization so that appropriate preventive actions can be implemented in beryllium-exposed industries; 4) to provide data related to the differential susceptibility conferred by specific genotypes so that preventive strategies can be devised for the most susceptible populations. In order to accomplish the objectives, it is necessary to have a genuine CBD mouse model exposed to beryllium. The purpose of this purchase order is to secure the services of an immunotoxicology expert to conduct exposure of the beryllium mouse model to different doses and different types of beryllium, and via different routes of administration (primarily skin versus lung). The outcome of the experiments will be measured by pathological quantification of lung granulomata and inflammation in animals sacrificed at 4 and 7 months. These outcomes will be determined by PPRB scientists in HELD/NIOSH. After validation of the animal model of CBD, dermal exposure will be evaluated as a possible route of sensitization. Based on an extensive literature search, we are confident that New York University School of Medicine is currently the only facility with a credible CBD mouse model, comprising three mouse strains with genetically engineered changes through ?knock-in? of members of the HLA-DPB1 gene family involved in CBD (one for each of the HLA-DPB1 family members, designated: *0201, *0401 and *1701). This notice is issued for informational purposes only. Any interested party must demonstrate in writing their ability to meet the requirements outlined above to the contracting officer no later than fifteen (15) days from the date of this announcement. Submit information to Rebecca Mullenax, Reference: 000HCCHB-2007-40608, DHHS/PHS/CDC/NIOSH/ALOSH, 1095 Willowdale Road, Morgantown, WV 26505 or Fax to 304-285-6083 or e-mail RMULLENAX@CDC.GOV. The intent of this synopsis is to determine if any sources exist, therefore, no solicitation will be issued. A determination by the Contracting Officer not to compete this action is solely within the discretion of the Government. If no responses are received within 15 days, award will be made to New York University School of Medicine without further notices being issued. All responses received shall be considered by the Government. Original Point of Contact Rebecca Mullenax, Purchasing Agent, Phone 304-285-5880, Fax 304-285-6083, Email RMULLENAX@CDC.GOV.
- Record
- SN01236601-W 20070224/070222220309 (fbodaily.com)
- Source
-
FedBizOpps Link to This Notice
(may not be valid after Archive Date)
| FSG Index | This Issue's Index | Today's FBO Daily Index Page |